Cardiff Oncology to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 21, 2022 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in fireside chats and 1×1…

Click here to view original post